Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
about
The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor CellsCirculating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionPhenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases.The promise of circulating tumor cells for precision cancer therapy.A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications.Circulating epithelial cell counts for monitoring the therapeutic outcome of patients with papillary thyroid carcinoma.The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.Circulating Tumor Cells: Markers and Methodologies for Enrichment and Detection.Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis.Improving the CellSearch® system.Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells.
P2860
Q26741223-DFFF92F0-13DB-40FC-AAA3-92BBE08181FBQ28066285-293C5D8A-FB14-48C8-AB9F-868BE993AE8CQ37688197-DB1CD9F6-EA80-4183-A522-8A80A33DC4BEQ38776791-36BED047-B1A5-4253-9F3F-E65CBDCD6FC7Q38838108-479197FB-702A-4677-9192-149B570A8D33Q39031157-3A08F448-2EFF-4862-9044-6C275464F822Q40152533-D2980721-DE03-4432-A5E0-660BA351F9BEQ42246492-524A00AE-C5D9-47D2-8DFD-D02ED3451602Q47138387-C53EA03D-573F-49CA-BCE8-B32375F6518DQ47146386-4ED89B98-60D5-4A99-A56F-FA44B5AF6E91Q47306138-9BF358E4-EABB-4181-A6FC-D77988859A49Q50114923-08BD412E-40DC-4319-AD9A-D4F4DBBC7A0BQ50199981-FFA5D24A-D974-4B30-B691-8ECC5C1D2754Q50449883-C8EC9707-9128-4965-9CCA-3FE1DCD6D774Q51115531-2CACDBC6-191D-4604-8E09-CD4D6B91C168Q52864004-7B818426-95A5-4643-A0A0-C30298D9EC49
P2860
Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@ast
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@en
type
label
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@ast
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@en
prefLabel
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@ast
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@en
P2093
P2860
P1433
P1476
Vimentin and Ki67 expression i ...... ate-resistant prostate cancer.
@en
P2093
C R Lindsay
M Ngo-Camus
S Le Moulec
P2860
P2888
P356
10.1186/S12885-016-2192-6
P407
P577
2016-02-29T00:00:00Z
P5875
P6179
1010912798